


122  
"Express Mail" mailing label number 56892945726US

Date of Deposit 8/18/03

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above. ~~Under the Addressed Mail Certification Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.~~  
Patents, P.O. Box 1450, Alexandria, VA 22313-1450



08-19-03  
RCE 1/100  
PTO/SB/30 (01-03)  
Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**Request  
For  
Continued Examination (RCE)  
Transmittal**

Address to:  
Commissioner for Patents  
P. O. Box 1450, Mail Stop RCE  
Alexandria, VA 22313-1450

Application Number	09/541,848
Filing Date	April 3, 2000
First Named Inventor	Chen
Art Unit	1635
Examiner Name	Schultz, James
Attorney Docket Number	HYB-015US4 (1006/016)

**This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.**  
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114**

- a. ☒ Previously submitted
- i. ☒ Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on May 2, 2003 (copy enclosed)  
(Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Rely Brief previously filed on \_\_\_\_\_
- iii. ☐ Other \_\_\_\_\_
- b. ☐ Enclosed
- i. ☐ Amendment/Reply
- ii. ☐ Affidavit(s)/ Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☐ Other \_\_\_\_\_

2. **Miscellaneous**

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other \_\_\_\_\_

3. **Fees**

- The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.  
The Director is hereby authorized to charge the following fees, or credit any overpayments, to
- a. ☐ Deposit Account No. 50-2285
- i. ☐ RCE fee required under 37 CFR 1.17(e) 08/20/2003 HBIZUNES 00000063 09541848
- ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17) 01 FC:2801 375.00 OP
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Check in the amount of \$ 580.00 enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print/Type)	Wayne A. Keown, Ph.D.	Registration No. (Attorney/Agent)	33,923
Signature	<i>Wayne A. Keown</i>	Date	8/15/03

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to: Commissioner For Patents, Mail Stop RCE, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Name (Print/Type)	<i>Metaneus L. Moore</i>	Date	<i>8/18/03</i>
Signature	<i>Metaneus L. Moore</i>		

Page 1 of 2

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Box RCE, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT  
ATTORNEY DOCKET NO. HYB-015US4  
SERIAL NO.: 09/541,848

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN APPLICATION OF:  
CHEN *et al.*

ART UNIT: 1635

EXAMINER: Wang, Andrew J.

SERIAL NO.: 09/541,848

FILED: April 3, 200

FOR: MDM2 SPECIFIC ANTISENES  
OLIGONUCLEOTIDES

\*\*\*\*\*

**CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. § 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date indicated below.

Date: 4/22/03

Signature Melissa A. Simpson

Printed Name: Melissa A. Simpson

\*\*\*\*\*

Box AF  
Assistant Commissioner for Patents  
Washington, DC 20231

**AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.116**

Dear Sir:

In response to the Final Office Action dated October 22, 2002, please reconsider the above-referenced patent application in view of the following amendment and remarks. Included with this response is a Request for an Extension of Time for 3 months under 37 C.F.R. § 1.136(a) and the appropriate fee.

"Express Mail" mailing label number EL89294572645  
Date of Deposit 8/18/03

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is address to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AMENDMENTS

LISTING OF THE CLAIMS

1. (Presently Amended) A method of inhibiting expression of MDM2 in a mammal, the method comprising administering to the mammal an effective MDM2-expression inhibiting amount of an anti-MDM2 antisense oligonucleotide, wherein said antisense oligonucleotide comprises from about 8 to about 50 nucleotides that inhibits MDM2 protein expression, said oligonucleotide binding to mdm2-encoding RNA and being complementary to a sequence that overlaps by at least one nucleotide a sequence within the mdm2 RNA, which sequence within the mdm2 RNA is selected from the group consisting of SEQ ID NOS: 2, 3, 4, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24.
2. The method according to claim 1 comprising co-administering a cancer chemotherapeutic agent.
3. The method according to claim 2, wherein the cancer therapeutic agent is 10-hydroxycamptothecin, adriamycin, or 5-fluorouracil.
4. The method according to claim 1 comprising co-treating the mammal with anti-cancer levels of radiation.
5. (Presently Amended) A method of inhibiting cancer *in vivo*, the method comprising administering a cancer-inhibiting amount of an anti-MDM2 antisense oligonucleotide, wherein the cancer involves over expression of MDM2, wherein said antisense oligonucleotide comprises from about 8 to about 50 nucleotides that inhibits MDM2 protein expression, said oligonucleotide binding to mdm2-encoding RNA and being complementary to a sequence that overlaps by at least one nucleotide a sequence within the mdm2 RNA, which sequence within the mdm2 RNA is selected from the